Literature DB >> 8555921

Third generation oral contraception and venous thromboembolism.

K McPherson.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1996        PMID： 8555921      PMCID： PMC2349743          DOI： 10.1136/bmj.312.7023.68

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  7 in total

1.  Smoking and death: the past 40 years and the next 40.

Authors:  R Peto
Journal:  BMJ       Date:  1994-10-08

Review 2.  Oral contraceptives and cardiovascular disease (first of two parts).

Authors:  B V Stadel
Journal:  N Engl J Med       Date:  1981-09-10       Impact factor: 91.245

3.  Enhancement by factor V Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing a third-generation progestagen.

Authors:  K W Bloemenkamp; F R Rosendaal; F M Helmerhorst; H R Büller; J P Vandenbroucke
Journal:  Lancet       Date:  1995-12-16       Impact factor: 79.321

4.  Venous thromboembolic disease and combined oral contraceptives: results of international multicentre case-control study. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception.

Authors: 
Journal:  Lancet       Date:  1995-12-16       Impact factor: 79.321

5.  Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestagen components.

Authors:  H Jick; S S Jick; V Gurewich; M W Myers; C Vasilakis
Journal:  Lancet       Date:  1995-12-16       Impact factor: 79.321

6.  Effect of different progestagens in low oestrogen oral contraceptives on venous thromboembolic disease. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception.

Authors: 
Journal:  Lancet       Date:  1995-12-16       Impact factor: 79.321

7.  Third generation oral contraceptives and risk of myocardial infarction: an international case-control study. Transnational Research Group on Oral Contraceptives and the Health of Young Women.

Authors:  M A Lewis; W O Spitzer; L A Heinemann; K D MacRae; R Bruppacher; M Thorogood
Journal:  BMJ       Date:  1996-01-13
  7 in total
  6 in total

1.  Symmetrical analysis of risk-benefit.

Authors:  John B Warren; Simon Day; Peter Feldschreiber
Journal:  Br J Clin Pharmacol       Date:  2012-11       Impact factor: 4.335

2.  Communication about risk--dilemmas for general practitioners. The Department of General Practice Working Group, University of Wales College of Medicine.

Authors:  A Edwards; L Prior
Journal:  Br J Gen Pract       Date:  1997-11       Impact factor: 5.386

3.  The statistical basis of public policy: a paradigm shift is overdue.

Authors:  R J Lilford; D Braunholtz
Journal:  BMJ       Date:  1996-09-07

Review 4.  Evidence-based medicine and general practice.

Authors:  L D Jacobson; A G Edwards; S K Granier; C C Butler
Journal:  Br J Gen Pract       Date:  1997-07       Impact factor: 5.386

5.  Third generation oral contraceptives. 12% of women stopped taking their pill immediately they heart CSM's warning.

Authors:  S Hope
Journal:  BMJ       Date:  1996-03-02

6.  Mortality from venous thromboembolism among young women in Europe: no evidence for any effect of third generation oral contraceptives.

Authors:  R D Farmer; R B Newson; K MacRae; R A Lawrenson; F Tyrer
Journal:  J Epidemiol Community Health       Date:  1997-12       Impact factor: 3.710
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.